Highest-materiality recent filing
UTMD's Femcare acquires Orion Medical Supplies for £3.6M; adds ~$6M annual sales
Femcare Ltd, UTMD subsidiary, bought all common shares of UK-based Orion Medical Supplies Ltd for £3.6M cash from reserves.
Q2 2026 revenue $8.53M, down 14.3% from $9.95M in Q2 2025; 1H revenue $17.25M, down 12.3%.
Shareholders re-elect Hoyer & Beeson, ratify auditor, approve say-on-pay at annual meeting
Ernst G. Hoyer re-elected with 1,330,333 for; 1,070,640 withheld; 372,329 broker non-votes.
Utah Medical Products announces Q1 2026 financial results; figures not available in filing
Press release attached as Exhibit 99.1 includes Q1 2026 financial information and forward-looking statements.
Utah Medical Products releases FY2025 earnings; no specifics in excerpt
Utah Medical Products reported Q4 and FY2025 results via press release dated January 29, 2026.
Utah Medical Products appoints director, increases quarterly dividend to $0.31/share
Appointed Kevin Timken to board, increasing size to 6; he joins Audit and Compensation committees.
Utah Medical Products Q3 2025 earnings released; financial data not available in excerpt
Q3 and nine-month period ended September 30, 2025 results reported via press release.
Utah Medical Products files 8-K with Q2 2025 results; specifics not extractable from filed text
Press release dated July 24, 2025 covers three and six months ended June 30, 2025.
Director Carrie Leigh received 665,574 for, 1,762,500 withheld; board did not accept her tendered resignation.
Utah Medical Products Q1 2025 results released; no specific figures in provided text
Q1 2025 financial results released on April 29, 2025 for Utah Medical Products.
UTMD reports Q4/FY2024 results; specific figures not available in filing excerpt
Press release dated Jan 28, 2025 contains financial data for three and twelve months ended Dec 31, 2024.
Utah Medical Products appoints director Carrie Leigh, raises dividend 1.7% to $0.305
Board increased to 6 members; appointed Carrie Leigh, daughter of CEO Kevin Cornwell, effective Nov 1, 2024.
Utah Medical Products Q3 2024 results referenced but data missing in filing extract
8-K filed Oct 29, 2024 furnishes press release for three and nine months ended Sep 30, 2024.
Utah Medical Products files Q2 2024 earnings release; detailed results not provided in filing text
Company furnished financial information for three and six months ended June 30, 2024 via press release dated July 25, 2024.
Paul Richins re-elected with 907,483 for vs 1,833,586 withheld; board declined his conditioned resignation.
Utah Medical Products Q1 2024 earnings released; key figures not provided in excerpt
Press release dated April 25, 2024 announces Q1 2024 financial results for Utah Medical Products.
UTMD FY2023 EPS up 1% on interest income; revenue down 4%, litigation costs rise
Full year revenue $50.2M (-4% YoY); EPS $4.574 (+1.2%) as lower operating income offset by higher interest income.
Utah Medical Products raises quarterly dividend to $0.30, up 1.7%
Quarterly dividend increased to $0.30 per share, a 1.7% rise from prior rate.
Utah Medical Products reports Q3 2023 results; financial data not provided in excerpt
Press release dated October 26, 2023 covers three and nine months ended September 30, 2023.
Utah Medical Products reports Q2/H1 2023 results; details not available in filing excerpt
Filing references a press release with financial results for three and six months ended June 30, 2023.
UTMD shareholders reject 2023 incentive plan; directors with low support remain
2023 Employees’ and Directors’ Incentive Plan voted down: 1,168,480 for vs 1,590,668 against.
UTMD Q1 2023: NI +19.2% to $4.2M, EPS $1.16; OUS sales +23%; cash $80.9M
Consolidated sales $12.5M, up 1.6% YoY; OUS sales up 23% (28% constant currency), domestic down 10%.
UTMD Q4 EPS $1.253, up 11% YoY; FY22 EPS $4.522, up 12%; dividend raised to $0.295
Q4 revenue $13.6M (+5.1% YoY); FY22 revenue $52.3M (+6.6% YoY); constant currency sales up ~10% for the year.
Utah Medical Products increases quarterly dividend to $0.295 per share
Regular quarterly cash dividend increased to $0.295 per share.
Utah Medical Products reports Q3 2022 earnings; no specific figures available in excerpt
Financial information for three and nine months ended September 30, 2022 is included.
Utah Medical Products reports Q2 2022 results; exhibit text incomplete in filing
Press release dated July 26, 2022 attached as Exhibit 99.1.
Utah Medical Products annual meeting votes: director elected, auditor ratified, say-on-pay approved
Barbara A. Payne elected as director: 1,765,558 for, 1,003,678 withheld, 418,237 broker non-votes.
UTMD Q1 2022 revenue +12.4%, EPS +16.6%; operating margin expands to 36.7%
Revenue $12.3M, up 12.4% YoY; domestic sales +18%, OUS +4% (constant currency +7%).
UTMD increases quarterly dividend 1.8% to $0.29/share
Quarterly dividend increased to $0.29/share, up 1.8% YoY.
UTMD Q4 EPS $1.127; FY2021 sales $49.1M, net income up 37% YoY
Diluted EPS Q4 $1.127 (up 20.6% YoY); FY GAAP EPS $4.041, non-GAAP $4.147.
Utah Medical Products declares $2.00 special dividend, replacing Q4 quarterly
Special cash dividend of $2.00/share, total ~$7.3M, payable Dec 29, 2021 to holders of record Dec 15.
UTMD Q3 2021 EPS $1.150, revenue up 20%; 9M non-GAAP EPS $3.021, up 46%
Q3 2021 net income $4.2M (33.5% of sales), up 43.4% YoY; diluted EPS $1.150.
UTMD Q2 net income up 161%, EPS $0.937; revenue $12.6M (+43%); guides FY EBITDA ~$25M
Q2 revenue $12.6M (+43% YoY); domestic +46%, OUS +40%; constant-currency sales +40%.
On November 1, 2024, the Board of Directors of Utah Medical Products, Inc. (UTMD) voted to increase the size of the Board of Directors from five to six members and to appoint Carrie Leigh to fill the vacancy created by the increase in the number of directors.
Max materiality 0.80 · Median 0.40 · Most common event earnings